Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

Stopped early · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with metastatic clear cell renal cell carcinoma (RCC). XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.

Key facts

Study ID

NCT00277316

Run by

Symphony Evolution, Inc.

People needed

11

Starts

2005-12-01

Expected to finish

2007-06-01

Last updated by the study team

2010-02-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females with histologically confirmed metastatic clear cell RCC
• Measurable disease according to Response Criteria for Solid Tumors (RECIST)
• No prior systemic cytotoxic chemotherapy
• Subjects who have received either no prior therapy for RCC, systemic immunotherapy only (such as interleukin-2 or interferon), or one agent targeting VEGF or a VEGFR (eg, bevacizumab, sorafenib, or sunitinib malate) may be enrolled
• ECOG performance status of 0 or 1
• Life expectancy ≥3 months
• Adequate organ and marrow function
• No other malignancies within 5 years
• Signed informed consent

You may not qualify if…

• Radiation to ≥25% of bone marrow within 30 days of XL999 treatment
• Subjects who have received systemic anticancer therapy within 30 days of XL999 treatment
• Subjects who have not recovered to grade ≤1 or to within 10% of baseline from adverse events due to medications administered >30 days prior to study enrollment
• History of or known brain metastases, current spinal cord compression or carcinomatous meningitis
• Uncontrolled and/or intercurrent illness
• Pregnant or breastfeeding females
• Known HIV

Where it is running

• Department of Hematology/Oncology — Los Angeles, California, United States
• Stanford Cancer Center — Palo Alto, California, United States
• Integrated Community Oncology Network — Jacksonville, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Joliet Oncology-Hematology Associates, Ltd — Joliet, Illinois, United States
• Division of Hematology/Oncology, Indiana University Cancer Center — Indianapolis, Indiana, United States
• The Cleveland Clinic Foundation Taussig Cancer Center — Cleveland, Ohio, United States
• Center for Oncology Research and Treatment, PA — Dallas, Texas, United States
• The Center for Cancer and Blood Disorders — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.